PMR articles available in PDF format contain expert market analyses, forecasts and commentaries on pharmaceuticals, medical and healthcare market in Central and Eastern Europe.
1 2 3 4 5 6 7 › »
Pharma market set to rebound in 2013 June 2013Oncological pharmaceuticals and immunosuppressive drugs were the driving force pushing the growth of the pharmaceutical market in 2008-2009. The main reason for the growth was the change in the status of immunosuppressive drugs from the category of medicines
Reimbursement Act had a strong impact on the pharmaceutical distribution segment in Poland April 2013The years 2013-2014 will be affected by the implications of the Reimbursement Act too, though the impact will be less severe than in 2012 which was a year of adjustment. As a result of continued declines in wholesale margins (down by 1 p.p. per year
Dermocosmetics distribution channels become more diversified in Poland January 2013In 2010-2011 the economic crisis had a particularly adverse effect on the market covered by our analysis. According to industry representatives, asked specifically for the purposes of the report, we are experiencing gradual market saturation –
Increase in imaging diagnostics market in Central Europe despite recession December 2012The increase in value between 2009 and 2012 in the overall imaging diagnostics market, understood as sales of equipment in six countries: Poland, Hungary, Romania, Bulgaria, the Czech Republic and Slovakia, has varied between 7% and 10% per annum. In
Rynek produktów OTC w Europie Środkowej przekroczy 5 mld euro w 2013 r. listopad 2012W 2011 r. sprzedaż apteczna produktów OTC w krajach Europy Środkowej1 wyniosła 4,4 mld euro (18,1 mld zł), co stanowiło wzrost o 5% rok do roku w euro. Pomiędzy 2012 and 2014 r. rynek ten powinien się rozwijać średniorocznie w tempie około 7%, do wartości
Rynek produktów OTC w Rosji, Ukrainie i Kazachstanie osiągnie 10 mld euro w 2014 r. listopad 2012Rynek produktów OTC w krajach WNP1 był wart 7,4 mld euro (30,5 mld zł) w 2011 r. co stanowiło wzrost o ponad 10% rok do roku w euro. W latach 2012-2014 rynek rozwijał się będzie w tempie 11% średniorocznie i osiągnie wartość 10 mld euro (ponad 41 mld
Public hospitals in Poland hope for changes in the funding of medical procedures November 2012The debt figure of SP ZOZ (independent public healthcare facilities) facilities exceeded PLN 10bn (€2.4bn) in 2011. The level of debts payable, i.e. whose maturity date has passed, increased by 9% to PLN 2.29bn (€0.56bn). At the end of Q2 2012
Pharma Poland News
Newsletter covering the pharmaceutical sector in Poland and containing news and analyses.